Mechanism of Action
BRIDION works differently than neostigmine by directly encapsulating, binding, and thus inactivating rocuronium or vecuronium.1-3
After intravenous injection, BRIDION distributes through the plasma and binds to the neuromuscular blocking agents rocuronium or vecuronium to form a complex.3 BRIDION does not affect the release or breakdown of acetylcholine.2
- The reduction of free rocuronium available in the blood plasma creates a concentration gradient with the neuromuscular junction.2
- As a result, there is a shift of rocuronium into the plasma, where it is encapsulated by BRIDION.2
- This process reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction, resulting in the reversal of neuromuscular blockade.
- The process is similar for vecuronium.
- The elimination half-life of BRIDION for adults with normal renal function is approximately 2 hours, with over 90% excreted within 24 hours, primarily in urine.